Novo Nordisk (NYSE: NVO) stock dropped over 2% due to an analyst’s downgrade. Market share declines for star drugs and disappointing clinical trial results are concerning. Competition from generics and Eli Lilly’s Zepbound pose challenges. Weight-loss drugs are popular, but caution is advised in investing in Novo Nordisk.

The Motley Fool Stock Advisor team did not include Novo Nordisk in their list of 10 best stocks to buy now. Past picks like Netflix and Nvidia have yielded significant returns. Novo Nordisk faces tough competition and challenges, so potential investors should proceed with caution when considering this stock.

Read more at Yahoo Finance: Why Novo Nordisk Stock Was Melting on Monday